Present expert consensus is that CRP is less useful for cardiovascular risk assessment in the setting of acute infection (3). In addition, the cardiovascular application of CRP testing in patients who have other systemic inflammatory disease is questionable. However, a marked increase in ischemic heart disease has been reported in patients with rheumatoid arthritis, a typical disease with significantly elevated CRP levels (59). This epidemiological observation raises the possibility that CRP can be useful in such patients. To date, however, there is insufficient evidence to provide guidance regarding appropriate cut points for cardiovascular risk stratification in patients who have other inflammatory diseases.
Was this article helpful?